Home Cart Sign in  
Chemical Structure| 1202759-32-7 Chemical Structure| 1202759-32-7

Structure of CNX-774
CAS No.: 1202759-32-7

Chemical Structure| 1202759-32-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CNX-774 is a potent and selective of Btk with IC50 < 1 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CNX-774

CAS No. :1202759-32-7
Formula : C26H22FN7O3
M.W : 499.50
SMILES Code : O=C(NC)C1=NC=CC(OC2=CC=C(NC3=NC=C(F)C(NC4=CC=CC(NC(C=C)=O)=C4)=N3)C=C2)=C1
MDL No. :MFCD26405992
InChI Key :VVLHQJDAUIPZFH-UHFFFAOYSA-N
Pubchem ID :59174579

Safety of CNX-774

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of CNX-774

RTK

Isoform Comparison

Biological Activity

Description
CNX-774, an orally active, irreversible, and selective BTK inhibitor with an IC50 of <1 nM, specifically targets Cysteine 481 of Btk for covalent modification [1][2].
Target
  • BTK

    BTK, IC50:<1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
S2-013 cells 100nM 72 hours CNX-774 sensitizes resistant cell lines to BQ PMC10305837
Human embryonic stem cell (hESC)-derived ventricular cardiomyocytes 0.1, 0.5, 1.0 μM 30 minutes To evaluate the electrophysiological effects of ibrutinib on ventricular cardiomyocytes, showing no significant effects PMC6524928
Human embryonic stem cell (hESC)-derived atrial cardiomyocytes 0.1, 0.5, 1.0 μM 30 minutes To evaluate the electrophysiological effects of ibrutinib on atrial cardiomyocytes, showing dose-dependent shortening of action potential duration (APD80) and prolongation of calcium transient duration (CaTD80) PMC6524928
MCF-7 cells 10 µM 24 hours K-145 reduced nuclear S1P, almost completely blocked H3-K9ac, HIF1α associated spheroid formation, and enhanced dead cells PMC7962096
MCF-7 cells 10 µM 24 hours K-145 reduced nuclear S1P, almost completely blocked H3-K9ac, HIF1α associated spheroid formation, and enhanced dead cells PMC7962096
KU812 cells 0.001-10 μmol/L 48 hours Inhibit the growth of KU812 cells PMC5655929
HMC-1 cells 0.001-10 μmol/L 48 hours Inhibit the growth of HMC-1 cells PMC5655929
Human basophils 0.001-1 μmol/L 30 minutes Inhibit IgE-dependent histamine release PMC5655929

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL6/J mice Immunocompetent pancreatic cancer mouse model Intraperitoneal injection 10 mg/kg Daily Combined targeting of DHODH and ENT1 dramatically suppressed tumor growth and prolonged mouse survival PMC10305837

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.00mL

0.40mL

0.20mL

10.01mL

2.00mL

1.00mL

20.02mL

4.00mL

2.00mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories